Paper4201225
Pseudomonas aeruginosa vaccine in cancer patients.
Young LS and 2 others. Ann Intern Med, 1973. Cited by 139 papers, by iCite.
Cite this record
ConductScience Library. Pseudomonas aeruginosa vaccine in cancer patients. Papers, record 4201225. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4201225
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacterial Vaccines | Major topic |
| Neoplasms | Major topic |
| Pseudomonas Infections | Major topic |
| Pseudomonas aeruginosa | Major topic |
| Vaccination | Major topic |
| Adult | |
| Antibodies, Bacterial | |
| Humans | |
| Immunization Schedule | |
| Leukopenia | |
| Prospective Studies | |
| Sepsis |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 139 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40821801 | Fc-modification of anti-PcrV gene-encoded antibodies modulates complement-mediated killing of Pseudomonas aeruginosa. | Front Immunol | 2025 | https://conductscience.org/library/papers/40821801 | PubMed |
| 40076637 | Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40076637 | PubMed |
| 37459522 | Immunization with lytic polysaccharide monooxygenase CbpD induces protective immunity against Pseudomonas aeruginosa pneumonia. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/37459522 | PubMed |
| 37432116 | Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target. | Microbiol Mol Biol Rev | 2023 | https://conductscience.org/library/papers/37432116 | PubMed |
| 35891262 | Pseudomonas aeruginosa: Recent Advances in Vaccine Development. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/35891262 | PubMed |
| 34066555 | Strategies to Tackle Antimicrobial Resistance: The Example of Escherichia coli and Pseudomonas aeruginosa. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34066555 | PubMed |
| 33291484 | Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine. | Cells | 2020 | https://conductscience.org/library/papers/33291484 | PubMed |
| 29547971 | Potential targets for next generation antimicrobial glycoconjugate vaccines. | FEMS Microbiol Rev | 2018 | https://conductscience.org/library/papers/29547971 | PubMed |
| 24575895 | Vaccines for Pseudomonas aeruginosa: a long and winding road. | Expert Rev Vaccines | 2014 | https://conductscience.org/library/papers/24575895 | PubMed |
| 21941090 | Recent developments for Pseudomonas vaccines. | Hum Vaccin | 2011 | https://conductscience.org/library/papers/21941090 | PubMed |
| 11035726 | Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. | Infect Immun | 2000 | https://conductscience.org/library/papers/11035726 | PubMed |
| 8132318 | Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06. | Infect Immun | 1994 | https://conductscience.org/library/papers/8132318 | PubMed |
| 7520416 | Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. | Infect Immun | 1994 | https://conductscience.org/library/papers/7520416 | PubMed |
| 6799548 | Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. | J Clin Invest | 1982 | https://conductscience.org/library/papers/6799548 | PubMed |
| 6793519 | Polysaccharide of the slime glycolipoprotein of Pseudomonas aeruginosa. | Infect Immun | 1981 | https://conductscience.org/library/papers/6793519 | PubMed |
| 6551339 | Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. | Infect Immun | 1983 | https://conductscience.org/library/papers/6551339 | PubMed |
| 6430805 | Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa. | Infect Immun | 1984 | https://conductscience.org/library/papers/6430805 | PubMed |
| 6429046 | Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice. | Infect Immun | 1984 | https://conductscience.org/library/papers/6429046 | PubMed |
| 6425224 | Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. | Infect Immun | 1984 | https://conductscience.org/library/papers/6425224 | PubMed |
| 6404816 | Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. | Infect Immun | 1983 | https://conductscience.org/library/papers/6404816 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4201225
GET https://conductscience.org/api/papers/v1/4201225/cited_by?page=2